关注
Hassan Alhazmi
Hassan Alhazmi
在 jazanu.edu.sa 的电子邮件经过验证
标题
引用次数
引用次数
年份
Modern approaches in the discovery and development of plant-based natural products and their analogues as potential therapeutic agents
A Najmi, SA Javed, M Al Bratty, HA Alhazmi
Molecules 27 (2), 349, 2022
2332022
FT-IR spectroscopy for the identification of binding sites and measurements of the binding interactions of important metal ions with bovine serum albumin
HA Alhazmi
Scientia Pharmaceutica 87 (1), 5, 2019
1342019
Thermophoresis for characterizing biomolecular interaction
M Asmari, R Ratih, HA Alhazmi, S El Deeb
Methods 146, 107-119, 2018
1242018
Medicinal plants and isolated molecules demonstrating immunomodulation activity as potential alternative therapies for viral diseases including COVID-19
HA Alhazmi, A Najmi, SA Javed, S Sultana, M Al Bratty, HA Makeen, ...
Frontiers in immunology 12, 637553, 2021
1022021
Targeting peroxisome proliferator‐activated receptors using thiazolidinediones: strategy for design of novel antidiabetic drugs
N Thangavel, M Al Bratty, S Akhtar Javed, W Ahsan, HA Alhazmi
International journal of medicinal chemistry 2017 (1), 1069718, 2017
892017
Phytochemical, Cytotoxic, and Antimicrobial Evaluation of the Fruits of Miswak Plant, Salvadora persica L.
M Al Bratty, HA Makeen, HA Alhazmi, SM Syame, AN Abdalla, ...
Journal of Chemistry 2020 (1), 4521951, 2020
782020
Novel pyridine and pyrimidine derivatives as promising anticancer agents: A review
M Albratty, HA Alhazmi
Arabian Journal of Chemistry 15 (6), 103846, 2022
752022
Development and validation of LC–MS/MS method for simultaneous determination of metformin and four gliptins in human plasma
M Al Bratty, HA Alhazmi, SA Javed, KG Lalitha, M Asmari, J Wölker, ...
Chromatographia 80, 891-899, 2017
702017
Treatment of SARS-CoV-2: How far have we reached?
W Ahsan, S Javed, M Al Bratty, HA Alhazmi, A Najmi
Drug discoveries & therapeutics 14 (2), 67-72, 2020
642020
Sulforaphane: A review of its therapeutic potentials, advances in its nanodelivery, recent patents, and clinical trials
B Mangla, S Javed, MH Sultan, P Kumar, K Kohli, A Najmi, HA Alhazmi, ...
Phytotherapy Research 35 (10), 5440-5458, 2021
612021
Cough suppressant herbal drugs: A review
S Sultana, A Khan, MM Safhi, HA Alhazmi
Int. J. Pharm. Sci. Invent 5 (5), 15-28, 2016
562016
Data quality in drug discovery: the role of analytical performance in ligand binding assays
H Wätzig, I Oltmann-Norden, F Steinicke, HA Alhazmi, M Nachbar, ...
Journal of computer-aided molecular design 29, 847-865, 2015
512015
Recent advances in affinity capillary electrophoresis for binding studies
HM Albishri, SE Deeb, N AlGarabli, R AlAstal, HA Alhazmi, M Nachbar, ...
Bioanalysis 6 (24), 3369-3392, 2014
512014
Bioactive natural antivirals: An updated review of the available plants and isolated molecules
S Mohan, MM Elhassan Taha, HA Makeen, HA Alhazmi, M Al Bratty, ...
Molecules 25 (21), 4878, 2020
502020
A comprehensive platform to investigate protein–metal ion interactions by affinity capillary electrophoresis
HA Alhazmi, M Nachbar, HM Albishri, D Abd El-Hady, S Redweik, ...
Journal of Pharmaceutical and Biomedical Analysis 107, 311-317, 2015
472015
Nanoparticles of resveratrol attenuates oxidative stress and inflammation after ischemic stroke in rats
M Ashafaq, MI Alam, A Khan, F Islam, G Khuwaja, S Hussain, R Ali, ...
International Immunopharmacology 94, 107494, 2021
442021
Metabolic stability assessment of new parp inhibitor talazoparib using validated lc–ms/ms methodology: In silico metabolic vulnerability and toxicity studies
MW Attwa, AA Kadi, AS Abdelhameed, HA Alhazmi
Drug design, development and therapy, 783-793, 2020
442020
Synthesis and evaluation of some new 1, 3, 4-oxadiazoles bearing thiophene, thiazole, coumarin, pyridine and pyridazine derivatives as antiviral agents
M Albratty, KA El-Sharkawy, HA Alhazmi
Acta pharmaceutica 69 (2), 261-276, 2019
412019
Graphene-based biosensors for disease theranostics: Development, applications, and recent advancements
HA Alhazmi, W Ahsan, B Mangla, S Javed, MZ Hassan, M Asmari, ...
Nanotechnology Reviews 11 (1), 96-116, 2021
392021
Investigation of metabolic degradation of new ALK inhibitor: Entrectinib by LC-MS/MS
MW Attwa, HW Darwish, HA Alhazmi, AA Kadi
Clinica Chimica Acta 485, 298-304, 2018
392018
系统目前无法执行此操作,请稍后再试。
文章 1–20